Citi analyst David Lebowitz initiated coverage of Incyte with a Buy rating and $82 price target. Incyte has built a multibillion-dollar franchise driven primarily by Jakafi, the analyst tells investors in a research note. While Jakafi patent expiration appears priced into the shares, in Opzelura, Incyte has another potential blockbuster opportunity, contends Citi. Considering the current Opzelura trajectory and stock price, the firm believes Incyte’s risk/reward profile is skewed positively.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on INCY:
- Syndax price target raised to $42 from $40 at Guggenheim
- Syndax and Incyte report topline data from the pivotal AGAVE-201 trial
- Incyte says Phase 3 TruE-AD3 study meets primary endpoint
- Incyte UK announces that MHRA granted authorization for Opzelura cream
- BTIG biotechnology analyst to hold an analyst/industry conference call